# VerImmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/verimmune

- Industry: Biotechnology
- Headquarters: Washington, US
- Website: www.verimmune.com/
- Total disclosed funding: $9M
- Latest round: Series A (Aug 27, 2024)
- Investors on record: 7

## About

Founded in 2019 by Joshua Wang (CEO) and based in Washington, US, VerImmune, Inc. operates as a developer of a biotechnology therapy that helps redirect the body’s pre-existing immunity to kill cancer cells. In November 2025, VerImmune Inc. raised USD 500,000 in venture funding from TEDCO.

The firm employs a proprietary technology engine called ViP (Virus-inspired Particle) based on the natural virology of papillomaviruses that improved targeting and helps in the development of various platform delivery medicine. The firm’s breakthrough solution is an anti-tumor immune redirection that treats cancer by harnessing the body's immune memory against pathogens and childhood vaccines.

The company will use the November 2025 funding to advance research on its ViP platform and progress VERI-101 toward clinical development.

## Funding rounds

- Series A, Aug 27, 2024, $4.5M — Gaingels, Proxima Ventures, Mana Ventures, Beiley Biofund
- Seed, Sep 20, 2023, $3.1M — Gaingels, Proxima Ventures, Mana Ventures
- Seed, Mar 18, 2022, $1.4M — Ulu Ventures, Gaingels, Proxima Ventures, Mana Ventures, SeedFolio, NuFund Venture Group

## Investors

- Ulu Ventures (https://capitalatlas.ai/funds/ulu-ventures) — Seed
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Seed, Series A
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Seed, Series A
- Mana Ventures (https://capitalatlas.ai/funds/mana-ventures) — Seed, Series A
- SeedFolio (https://capitalatlas.ai/funds/seedfolio) — Seed
- NuFund Venture Group (https://capitalatlas.ai/funds/nufund-venture-group) — Seed
- Beiley Biofund (https://capitalatlas.ai/funds/beiley-biofund) — Series A